BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28693243)

  • 1. RT-qPCR for
    Grèze V; Kanold J; Chambon F; Halle P; Gremeau AS; Rives N; Rouel N; Pereira B; Tchirkov A; Brugnon F
    Oncol Lett; 2017 Jul; 14(1):860-866. PubMed ID: 28693243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly sensitive assessment of neuroblastoma minimal residual disease in ovarian tissue using RT-qPCR-A strategy for improving the safety of fertility restoration.
    Grèze V; Brugnon F; Chambon F; Halle P; Canis M; Amiot C; Grémeau AS; Pereira B; Yáñez Peralta Y; Tchirkov A; Kanold J
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27734578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
    Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Yalcin B; Dee R; van Noesel MM; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    Clin Chem; 2009 Jul; 55(7):1316-26. PubMed ID: 19460840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma.
    Ito R; Asami S; Kagawa S; Motohashi S; Shichino H; Chin M; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
    Biol Pharm Bull; 2004 Mar; 27(3):315-8. PubMed ID: 14993794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive and Specific Detection of Ewing Sarcoma Minimal Residual Disease in Ovarian and Testicular Tissues in an In Vitro Model.
    Chaput L; Grèze V; Halle P; Radosevic-Robin N; Pereira B; Véronèse L; Lejeune H; Durand P; Martin G; Sanfilippo S; Canis M; Kanold J; Tchirkov A; Brugnon F
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31744224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RT-PCR demonstrates superior sensitivity and specificity in detecting the five neuroblastoma genes compared to the flow cytometry method for measurable residual disease.
    Tian X; Li H; Luo T; Mao J; Yuan X; Gao Q; Xiao J; Qian S; Zou R; Chen K; Zhu C; Yi C; He X
    Transl Pediatr; 2023 Dec; 12(12):2232-2246. PubMed ID: 38197110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK cytotoxicity and alloreactivity against neuroblastoma cell lines in vitro: comparison of Europium fluorometry assay and quantification by RT-PCR.
    Paillard C; Halle P; Tchirkov A; Confland C; Veyrat-Masson R; Quainon F; Perreira B; Rochette E; Pfeiffer M; Lang P; Deméocq F; Kanold J
    J Immunol Methods; 2012 Jun; 380(1-2):56-64. PubMed ID: 22516232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.
    Viprey VF; Gregory WM; Corrias MV; Tchirkov A; Swerts K; Vicha A; Dallorso S; Brock P; Luksch R; Valteau-Couanet D; Papadakis V; Laureys G; Pearson AD; Ladenstein R; Burchill SA
    J Clin Oncol; 2014 Apr; 32(10):1074-83. PubMed ID: 24590653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
    Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of PHOX2B in primary and treated neuroblastoma and in neuroblastoma metastatic to the bone marrow.
    Hata JL; Correa H; Krishnan C; Esbenshade AJ; Black JO; Chung DH; Mobley BC
    Arch Pathol Lab Med; 2015 Apr; 139(4):543-6. PubMed ID: 25822764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.
    Druy AE; Shorikov EV; Tsaur GA; Popov AM; Zaychikov AN; Tuponogov SN; Saveliev LI; Tytgat GAM; Fechina LG
    Pediatr Blood Cancer; 2018 Nov; 65(11):e27354. PubMed ID: 30007008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
    Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
    Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined analysis of PHOX2B at two time points and its value for further risk stratification in high-risk neuroblastoma.
    Yue Z; Gao C; Xing T; Zhao W; Duan C; Wang X; Jin M; Su Y
    Pediatr Blood Cancer; 2023 May; 70(5):e30261. PubMed ID: 36815592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The TH, ELAVL4 and GD2 gene expression as diagnostic markers of bone marrow lesions in patients with neuroblastoma].
    Druĭ AE; Tsaur GA; Popov AM; Tuponogov SN; Shorikov EV; Tsvirenko SV; Savel'ev LI; Fechina LG
    Vopr Onkol; 2012; 58(4):514-20. PubMed ID: 23607207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of β-catenin and paired-like homeobox 2B (PHOX2B) expression in neuroblastoma patients; predictive and prognostic value.
    El-Shazly SS; Hassan NM; Abdellateif MS; El Taweel MA; Abd-Elwahab N; Ebeid EN
    Exp Mol Pathol; 2019 Oct; 110():104272. PubMed ID: 31220430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of neuroblastoma cells during clinical follow up: advanced flow cytometry and rt-PCR for tyrosine hydroxylase using both conventional and real-time PCR.
    Esser R; Glienke W; Bochennek K; Erben S; Quaiser A; Pieper C; Eggert A; Schramm A; Astrahantseff K; Hansmann ML; Schwabe D; Klingebiel T; Koehl U
    Klin Padiatr; 2011 Nov; 223(6):326-31. PubMed ID: 22095188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of survivin mRNA expression in prognosis of neuroblastoma.
    Ito R; Asami S; Motohashi S; Ootsuka S; Yamaguchi Y; Chin M; Shichino H; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
    Biol Pharm Bull; 2005 Apr; 28(4):565-8. PubMed ID: 15802787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.
    Kuroda T; Saeki M; Nakano M; Mizutani S
    J Pediatr Surg; 1997 Jan; 32(1):69-72. PubMed ID: 9021573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.